A trial of olaparib for ovarian cancer with a change to a BRCA gene that responded to platinum chemotherapy (SOLO2)

Please note

This trial is no longer recruiting patients. We hope to add results when they are available.

Overview

Cancer types:

Ovarian cancer

Status:

Closed

Phase:

Phase 3

Details

This trial is looking at a drug called olaparib for ovarian cancer, fallopian tube cancer or primary peritoneal cancer that has a change to a gene called BRCA1 or BCRA2.

Recruitment start: 26 November 2013

Recruitment end: 10 October 2014

How to join

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Professor Jonathan Ledermann

Supported by

AstraZeneca

Experimental Cancer Medicine Centre (ECMC)

NIHR Clinical Research Network: Cancer

Last reviewed: 24 November 2014

CRUK internal database number: 11334

Dangoor Education

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

Help and support

Questions for your doctor

What to ask your doctor about clinical trials.

Cancer chat forum

Meet and chat to other cancer people affected by cancer.

Nurse helpline

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.